# Lymphoma, Mantle Cell FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/lymphoma-mantle-cell

> 4 upcoming FDA catalysts in lymphoma, Mantle Cell: Calquence (acalabrutinib, AZN) on Feb to May 2027 (topline data readout); Calquence (acalabrutinib, AZN) on February 2027 (primary completion); Jaypirca (pirtobrutinib, LLY) on November 2027 (primary completion); Jaypirca (pirtobrutinib, LLY) on Nov 2027 to Feb 2028 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Feb to May 2027 | [Calquence (acalabrutinib) topline data readout](https://sec-api.dev/pdufa/acalabrutinib) | AZN | Lymphoma, Mantle Cell | scheduled | "NCT02972840 (A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-15 (ESTIMATED); Lead Sponsor Acerta Pharma BV." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02972840)) |
| February 2027 | [Calquence (acalabrutinib) primary completion](https://sec-api.dev/pdufa/acalabrutinib) | AZN | Lymphoma, Mantle Cell | scheduled | "NCT02972840 (A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-15 (ESTIMATED); Lead Sponsor Acerta Pharma BV." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02972840)) |
| November 2027 | [Jaypirca (pirtobrutinib) primary completion](https://sec-api.dev/pdufa/pirtobrutinib) | LLY | Lymphoma, Mantle-Cell | scheduled | "NCT04662255 (Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Loxo Oncology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04662255)) |
| Nov 2027 to Feb 2028 | [Jaypirca (pirtobrutinib) topline data readout](https://sec-api.dev/pdufa/pirtobrutinib) | LLY | Lymphoma, Mantle-Cell | scheduled | "NCT04662255 (Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Loxo Oncology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04662255)) |

## Drugs

- [Calquence (acalabrutinib)](https://sec-api.dev/pdufa/acalabrutinib) (AZN)
- [Jaypirca (pirtobrutinib)](https://sec-api.dev/pdufa/pirtobrutinib) (LLY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/lymphoma-mantle-cell.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Lymphoma, Mantle Cell FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/lymphoma-mantle-cell

```bibtex
@misc{secapidev_indications_lymphoma_mantle_cell_20261116,
  title        = {Lymphoma, Mantle Cell FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/lymphoma-mantle-cell}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_lymphoma_mantle_cell_20261116","title":"Lymphoma, Mantle Cell FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/lymphoma-mantle-cell","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
